<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30133">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01947517</url>
  </required_header>
  <id_info>
    <org_study_id>Punctal plugs</org_study_id>
    <nct_id>NCT01947517</nct_id>
  </id_info>
  <brief_title>The Retention Rate Between Brand A and Brand B Punctal Plugs</brief_title>
  <official_title>The Retention Rate Between Superflex Punctal Plugs, and Parasol Punctal Occluders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Parasol punctal occluders (Brand A) have a
      higher rate of retention than Superflex punctal plugs (Brand B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eyes will be randomized to either Brand A or Brand B punctal plug.  The primary outcome
      measure is length of time punctual plugs are retained, measured in weeks.  This will be
      measured at weekly assessments for 6 months.  Secondary outcome measures include patient
      satisfaction, and improvement in subjective and objective dry eye scores, as well as
      complications related to punctual plugs including spontaneous plug loss, and intolerance.
      We will evaluate these measures by repeating the Canadian Dry Eye Assessment, Schirmer 1,
      tear meniscus height, fluorescein corneal staining (NEI scale), and lissamine green
      conjunctival staining (NEI scale) at month 1, month 3, and month 6 visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Length of retention</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Canadian Dry Eye Assessment scores</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in corneal fluorescein staining</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in lissamine green conjunctival staining</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in tear meniscus height</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Moderate to Severe Dry Eye</condition>
  <arm_group>
    <arm_group_label>Parasol Group</arm_group_label>
    <description>Randomized to receive Brand A punctal plugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Superflex Group</arm_group_label>
    <description>Randomized to receive Group B punctal plugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Parasol Punctal Occluder</intervention_name>
    <arm_group_label>Parasol Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Superflex Punctal Occluder</intervention_name>
    <arm_group_label>Superflex Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from cornea and general ophthalmology specialist practices at
        Hotel Dieu Hospital, Queens University
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate dry eye, severe dry eye

        Exclusion Criteria:

          -  silicone allergy, punctal stenosis, punctal occlusion, punctal cautery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley R Brissette, BSc, MD</last_name>
    <role>Study Director</role>
    <affiliation>Queens University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephanie Baxter, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queens University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley R Brissette, BSc, MD</last_name>
    <phone>613 544 3310</phone>
    <email>abrissette@qmed.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology, Hotel Dieu Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley R Brissette, BSc, MD</last_name>
      <phone>613 544 3310</phone>
      <email>abrissette@qmed.ca</email>
    </contact>
    <investigator>
      <last_name>Stephanie Baxter, MD FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Bona, MD FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Schweitzer, MD FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley R Brissette, BSc MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 26, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Stephanie Baxter</investigator_full_name>
    <investigator_title>Program Director Department of Ophthalmology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
